All News

Male scientists are more likely to file patents on their research than their female colleagues.

A driving force in the growing demand for MEMS could be pressure to make cars safer.

A reminder that it isn't just nanotechnology that can make money for businesses wanting to work on a small scale.

It may be that the similarity between the name of a US memory chip supplier, Rambus, and that of a rebel and indomitable hero, Rambo, is purely coincidental. Yet, looking at the story of Rambus, it is difficult to avoid comparisons.

Public procurement should be used to stimulate innovation using a US model that has proved itself over 25 years, says a report from the University of Cambridge, UK.

Weighing conflicting views of the outlook for European biotechnology was the object of a conference 13 June at the Karolinska Institutet in Stockholm.

A survey of 449 European businesses shows that they plan to increase their spending on R&D by 5% a year for the next three years.

In a landmark deal for Asia, the first takeover of European biotech firms by a counterpart in Singapore has been finalised.

Asian R&D is hot. Witness our summertime sampling of news tidbits – some important, some just bizarre.

SMEs are the target for a new "portal" on the European Nanotechnology Gateway, nanoforum.org

The US Department of Energy plans to put $1.4 million for studies on the economic feasibility of producing hydrogen at nuclear plants.

Not quite the newest technology on the block, but a new Chinese factory is ramping up productuion of tiny particles.

Google has so many irons in the fire that it is not always easy to keep track of its projects. This is definitely not the case of the Google Library project, which proposes to scan the content of great libraries of the world and make them accessible to on-line search.

Unlike old generals, drug-patent wars not only do not die but do not even fade away. As reported by Reuters and other major media, on Monday, August 7, hundreds of Thais living with HIV/AIDS demonstrated in front of the Bangkok offices of drug maker GlaxoSmithKline to protest a patent application for its key anti-retroviral drug, Combid.